Drug resistance via feedback activation of stat3 in oncogene-addicted cancer cells

Cancer Cell

Volumn 26, Issue 2, 2014, Pages 207-221

  Lee, Ho June ^a   Zhuang, Guanglei ^a   Cao, Yi ^a   Du, Pan ^a   Kim, Hyo Jin ^a   Settleman, Jeff ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; COBIMETINIB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; GEFITINIB; JANUS KINASE; K RAS PROTEIN; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PONATINIB; RUXOLITINIB; SCATTER FACTOR RECEPTOR; SELUMETINIB; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOCRINE EFFECT; CANCER CELL; CANCER PATIENT; CANCER RESISTANCE; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; ONCOGENE; POSITIVE FEEDBACK; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR REGRESSION; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; IMIDAZOLES; INTERLEUKIN-6; JANUS KINASE 1; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MICE; MICE, SCID; MUTATION; ONCOGENES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PYRAZOLES; PYRIDAZINES; QUINAZOLINES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84905726946     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.05.019     Document Type: Article

References (39)

1. Anders S., Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010, 11:R106.
2. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
3. Bromberg J. Stat proteins and oncogenesis. J.Clin. Invest. 2002, 109:1139-1142.
4. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., Darnell J.E. Stat3 as an oncogene. Cell 1999, 98:295-303.
5. Chandarlapaty S., Sawai A., Scaltriti M., Rodrik-Outmezguine V., Grbovic-Huezo O., Serra V., Majumder P.K., Baselga J., Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011, 19:58-71.
6. Daub H., Specht K., Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat. Rev. Drug Discov. 2004, 3:1001-1010.
7. Duncan J.S., Whittle M.C., Nakamura K., Abell A.N., Midland A.A., Zawistowski J.S., Johnson N.L., Granger D.A., Jordan N.V., Darr D.B., et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012, 149:307-321.
8. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
9. Guryanova O.A., Wu Q., Cheng L., Lathia J.D., Huang Z., Yang J., MacSwords J., Eyler C.E., McLendon R.E., Heddleston J.M., et al. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell 2011, 19:498-511.
10. Györffy B., Lanczky A., Eklund A.C., Denkert C., Budczies J., Li Q., Szallasi Z. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res. Treat. 2010, 123:725-731.
11. Haber D.A., Gray N.S., Baselga J. The evolving war on cancer. Cell 2011, 145:19-24.
12. Holohan C., Van Schaeybroeck S., Longley D.B., Johnston P.G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 2013, 13:714-726.
13. Huang Q., Li F., Liu X., Li W., Shi W., Liu F.F., O'Sullivan B., He Z., Peng Y., Tan A.C., et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat. Med. 2011, 17:860-866.
14. Hutti J.E., Pfefferle A.D., Russell S.C., Sircar M., Perou C.M., Baldwin A.S. Oncogenic PI3K mutations lead to NF-κB-dependent cytokine expression following growth factor deprivation. Cancer Res. 2012, 72:3260-3269.
15. Kim S.M., Kwon O.J., Hong Y.K., Kim J.H., Solca F., Ha S.J., Soo R.A., Christensen J.G., Lee J.H., Cho B.C. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol. Cancer Ther. 2012, 11:2254-2264.
16. Koskela H.L., Eldfors S., Ellonen P., van Adrichem A.J., Kuusanmäki H., Andersson E.I., Lagström S., Clemente M.J., Olson T., Jalkanen S.E., et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N.Engl. J. Med. 2012, 366:1905-1913.
17. Krysko D.V., Vandenabeele P. From regulation of dying cell engulfment to development of anti-cancer therapy. Cell Death Differ. 2008, 15:29-38.
18. Lee H.J., Schaefer G., Heffron T.P., Shao L., Ye X., Sideris S., Malek S., Chan E., Merchant M., La H., et al. Noncovalent wild-type-sparing inhibitors of EGFR T790M. Cancer Discov 2013, 3:168-181.
19. Lito P., Rosen N., Solit D.B. Tumor adaptation and resistance to RAF inhibitors. Nat. Med. 2013, 19:1401-1409.
20. O'Hare T., Shakespeare W.C., Zhu X., Eide C.A., Rivera V.M., Wang F., Adrian L.T., Zhou T., Huang W.S., Xu Q., et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009, 16:401-412.
21. Pilati C., Amessou M., Bihl M.P., Balabaud C., Nhieu J.T., Paradis V., Nault J.C., Izard T., Bioulac-Sage P., Couchy G., et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J.Exp. Med. 2011, 208:1359-1366.
22. Prahallad A., Sun C., Huang S., Di Nicolantonio F., Salazar R., Zecchin D., Beijersbergen R.L., Bardelli A., Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103.
23. Roesch A., Fukunaga-Kalabis M., Schmidt E.C., Zabierowski S.E., Brafford P.A., Vultur A., Basu D., Gimotty P., Vogt T., Herlyn M. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010, 141:583-594.
24. Sharma S.V., Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 2007, 21:3214-3231.
25. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 2007, 7:169-181.
26. Sharma S.V., Lee D.Y., Li B., Quinlan M.P., Takahashi F., Maheswaran S., McDermott U., Azizian N., Zou L., Fischbach M.A., et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
27. Shuai K., Horvath C.M., Huang L.H., Qureshi S.A., Cowburn D., Darnell J.E. Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell 1994, 76:821-828.
28. Singh A., Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29:4741-4751.
29. Smyth G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 2004, 3:e3.
30. Sos M.L., Koker M., Weir B.A., Heynck S., Rabinovsky R., Zander T., Seeger J.M., Weiss J., Fischer F., Frommolt P., et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 2009, 69:3256-3261.
31. Straussman R., Morikawa T., Shee K., Barzily-Rokni M., Qian Z.R., Du J., Davis A., Mongare M.M., Gould J., Frederick D.T., et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487:500-504.
32. Vultur A., Villanueva J., Krepler C., Rajan G., Chen Q., Xiao M., Li L., Gimotty P.A., Wilson M., Hayden J., et al. MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines. Oncogene 2014, 33:1850-1861.
33. Wang S.E., Narasanna A., Perez-Torres M., Xiang B., Wu F.Y., Yang S., Carpenter G., Gazdar A.F., Muthuswamy S.K., Arteaga C.L. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006, 10:25-38.
34. Wang X., Crowe P.J., Goldstein D., Yang J.L. STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review). Int. J. Oncol. 2012, 41:1181-1191.
35. Wen Z., Zhong Z., Darnell J.E. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995, 82:241-250.
36. Wilson T.R., Fridlyand J., Yan Y., Penuel E., Burton L., Chan E., Peng J., Lin E., Wang Y., Sosman J., et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012, 487:505-509.
37. Wu T.D., Nacu S. Fast and SNP-tolerant detection of complex variants and splicing in short reads. Bioinformatics 2010, 26:873-881.
38. Yonesaka K., Zejnullahu K., Lindeman N., Homes A.J., Jackman D.M., Zhao F., Rogers A.M., Johnson B.E., Jänne P.A. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin. Cancer Res. 2008, 14:6963-6973.
39. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9:798-809.